Category: Federal Forum Posters
Purpose: Sublingual buprenorphine use has increased for treatment of complex persistent opioid dependence (CPOD) and other long-term opioid therapy related problems, such as ineffectiveness, aberrancy, safety issues, and complications of opioid dose reduction or cessation; however, very little is known about the clinical characteristics, treatment retention, and healthcare utilization patterns of this patient population. Therefore, there is a need for increased knowledge in patients with CPOD regarding these patterns when compared to patients with non-therapeutically acquired opioid use disorder (OUD).
Methods: There are two phases to this study. The first phase will consist of a retrospective chart review of the first fifty patients initiated on buprenorphine for CPOD and pain between March 1, 2017 and October 15, 2017 in primary care and matched with the first fifty patients started in specialty mental health settings during the same timeframe for non-therapeutically acquired OUD. An index date will be specific to each individual and defined as the date in which they were first prescribed buprenorphine. The second phase of the study will consist of a retrospective cost analysis of healthcare utilization by each patient for one year preceding initiation date of buprenorphine for CPOD (three hundred sixty-five days prior to index date for each individual patient) and comparing it to their healthcare utilization one year post-initiation of buprenorphine (three hundred sixty-five days following the index date for each individual patient). A chart review will be conducted for all patients to assess for treatment retention.
Results: Not applicable
Conclusion: Not applicable
Brigit Kirwan– PGY1 Pharmacy Resident, Hampton VA Medical Center, Hampton, VA